<DOC>
	<DOC>NCT01990144</DOC>
	<brief_summary>The purpose of the study is to evaluate feasibility and efficacy of rituximab-bendamustine (R-B)combination in elderly patients affected by diffuse large B-cell lymphoma and defined as frail according to CGA.</brief_summary>
	<brief_title>Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (&gt;70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically proven CD20 positive diffuse large Bcell nonHodgkin's lymphoma Age &gt; 70 years No previous treatment FRAIL patients defined as follows (see Appendices BE) Age &gt; 80 years with UNFIT profile, i.e. ADL &gt; 5 residual functions IADL &gt; 6 residual functions CIRS 58 comorbidities of grade 2 or Age &lt; 80 years with ADL &lt; 4 residual functions, or IADL &lt; 5 residual functions, or CIRS : 1 comorbidity of grade 34, or &gt; 8 comorbidities of grade 2 Life expectancy &gt; 6 months Written informed consent Accessibility of patient for treatment and follow up History of other malignancies within 5 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer Previous exposure to cytotoxic agents Suspect or clinical evidence of CNS involvement by lymphoma HBsAg, HCV or HIV positivity; HBcAb positivity is accepted only with concomitant treatment with Lamivudine AST /ALT &gt; twice upper the normal range; bilirubin &gt; twice upper the normal range; serum creatinine &gt; 2.5 mg /dl Evidence of any severe active acute or chronic infection Concurrent comorbid medical condition which might exclude administration of full dose chemotherapy Senile dementia Any other coexisting medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>